Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis
CONCLUSION: T2DM represents a risk factor for the insurgence of pNET and is a significant predictor of poor post-treatment TFS of pNET patients. Unfortunately, a few studies with heterogeneous results limited the possibility of exploring the effect of metformin in the diagnosis and prognosis of pNET.PMID:38515954 | PMC:PMC10950617 | DOI:10.3748/wjg.v30.i7.759
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Maja Cigrovski Berkovic Alessandro Coppola Vibor Sesa Anna Mrzljak Quirino Lai Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Gastroenterology | Metformin | Neurology | Pancreas | Pancreatic Cancer | Statistics | Study | Toxicology